Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Alexander Drilon, MD, discusses the safety profile of brigatinib in ALK-positive non­–small cell lung cancer.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.

A pair of fellows will be able to advance their innovative technology-based projects thanks to the OncLive® Innovation Challenge: Innovative Technology in Cancer Care.

Faculty from Memorial Sloan Kettering Cancer Center shed light on some of the intriguing research in hematologic cancer being conducted at their institution.

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial in patients with previously untreated chronic lymphocytic leukemia.

Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses the use of lung-sparing surgery in early-stage lung cancer.

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.

Anthony R. Mato, MD, MSCE, discusses recent treatment advances that have been made in the frontline and relapsed/refractory settings of chronic lymphocytic leukemia.

Eileen O'Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses investigational treatment approaches in advanced pancreatic cancer.

Robert J. Motzer, MD, discusses the current frontline treatment landscape of metastatic renal cell carcinoma amongst an influx of approvals.

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

David H. Ilson, MD, PhD, discusses remaining challenges with immunotherapy in gastric cancer.

Eytan M. Stein, MD, discusses the introduction of novel agents, the relevancy of chemotherapy, and assessing minimal residual disease in acute myeloid leukemia.

Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma.

Jae H. Park, MD, discusses how emerging agents across several treatment modalities are demonstrating great potential in acute lymphoblastic leukemia.

Mark E. Robson, MD, provides a snapshot of the precision focus in breast cancer, as well as the emergence of biosimilars in the field.

Sham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

Alison J. Moskowitz, MD, discusses pivotal data for brentuximab vedotin in Hodgkin and T-Cell Lymphoma, as well as other ongoing developments in these paradigms.

Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Miguel-Angel Perales, MD, discusses the use of CAR T-cell therapy in diffuse large B-cell lymphoma and transformed follicular lymphoma.

Eytan M. Stein, MD, discusses the importance of measuring for measurable residual disease in acute myeloid leukemia.

Raajit K. Rampal, MD, PhD, discusses current available treatments for patients with polycythemia vera and myelofibrosis, as well as the unmet needs in this area of research.

Sergio A. Giralt, MD, discusses the current frontline standard of care for patients with multiple myeloma.

Sham Mailankody, MBBS, discusses ongoing research and recent advances in relapsed/refractory multiple myeloma.

Alexander Drilon, MD, discusses performing comprehensive sequencing in lung cancer.

Jamie E. Chaft, MD, explains how the PACIFIC trial has impacted the treatment of patients with stage III unresectable non–small cell lung cancer and the research being done to move immunotherapy into the neoadjuvant setting.

Sergio A. Giralt, MD, discusses the changing frontline treatment setting in multiple myeloma, how to determine transplant eligibility, and the utility of testing for minimal residual disease negativity.